Immunovant Income Statement

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2018 - 2020
Period Ending	Jun '25 Jun 30, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021	2018 - 2020
Selling, General & Admin	84.45	77.24	57.28	48.02	54.23	39.51	Upgrade
Research & Development	386.64	360.92	212.93	160.26	101.81	68.6	Upgrade
Operating Expenses	471.1	438.15	270.21	208.28	156.03	108.12	Upgrade
Operating Income	-471.1	-438.15	-270.21	-208.28	-156.03	-108.12	Upgrade
Interest & Investment Income	23.89	24.73	24.95	7.58	-	-	Upgrade
Other Non Operating Income (Expenses)	1.63	0.47	-1.01	-0.25	-0.78	0.33	Upgrade
EBT Excluding Unusual Items	-445.58	-412.95	-246.27	-200.95	-156.81	-107.79	Upgrade
Pretax Income	-445.58	-412.95	-258.77	-210.95	-156.81	-107.79	Upgrade
Income Tax Expense	1.73	0.89	0.57	0.01	-0.08	-0.36	Upgrade
Net Income	-447.3	-413.84	-259.34	-210.96	-156.73	-107.43	Upgrade
Net Income to Common	-447.3	-413.84	-259.34	-210.96	-156.73	-107.43	Upgrade
Shares Outstanding (Basic)	158	152	138	123	110	88	Upgrade
Shares Outstanding (Diluted)	158	152	138	123	110	88	Upgrade
Shares Change (YoY)	11.11%	9.76%	12.21%	12.21%	24.98%	103.14%	Upgrade
EPS (Basic)	-2.84	-2.73	-1.88	-1.71	-1.43	-1.22	Upgrade
EPS (Diluted)	-2.84	-2.73	-1.88	-1.71	-1.43	-1.22	Upgrade
Free Cash Flow	-417.66	-376.63	-214.59	-188.39	-106.37	-83.54	Upgrade
Free Cash Flow Per Share	-2.65	-2.48	-1.55	-1.53	-0.97	-0.95	Upgrade
EBITDA	-470.69	-437.78	-269.98	-208.08	-155.91	-108.05	Upgrade
D&A For EBITDA	0.4	0.38	0.23	0.19	0.13	0.07	Upgrade
EBIT	-471.1	-438.15	-270.21	-208.28	-156.03	-108.12	Upgrade

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q